| Literature DB >> 30175073 |
Claudia I Brodskyn1, Shaden Kamhawi2.
Abstract
In Latin America, zoonotic visceral leishmaniasis (ZVL) arising from infection by L. infantum is primarily transmitted by Lutzomyia longipalpis sand flies. Dogs, which are chronic reservoirs of L. infantum, are considered a significant risk factor for acquisition of ZVL due to their close proximity to humans. In addition, as a vector-borne disease the intensity of exposure to vector sand flies can also enhance the risk of developing ZVL. Traditionally, IFN-γ and IL-10 are considered as the two main cytokines which determine the outcome of visceral leishmaniasis. However, more recently, the literature has demonstrated that different mediators, such as lipid mediators (PGE-2, PGF-2 alfa, LTB-4, resolvins) and other important inflammatory and anti-inflammatory cytokines are also involved in the pathogenicity of ZVL. Analysis of a greater number of mediators allows for a more complete view of disease immunopathogenesis. Additionally, our knowledge has expanded to encompass different biomarkers associated to disease severity and healing after specific treatments. These parameters can also be used to better define new potential targets for vaccines and chemotherapy for ZVL. Here, we will provide an overview of ZVL biomarkers identified for both humans and dogs and discuss their merits and shortcomings. We will also discuss biomarkers of vector exposure as an additional tool in our arsenal to combat ZVL.Entities:
Keywords: Leishmania infantum; biomarkers; canine visceral leishmaniasis; cytokines/chemokines; human visceral leishmaniasis; zoonotic visceral leishmaniasis
Mesh:
Substances:
Year: 2018 PMID: 30175073 PMCID: PMC6108378 DOI: 10.3389/fcimb.2018.00245
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Biomarkers for human visceral leishmaniasis.
| IFN-γ, IL-12, and IL- 10 TNFα, IL-17 | sCD4, sCD8, and sIL2R | ↑ Active disease | Schriefer et al., | ||
| ↓ Post-treatment | Nylen and Sacks, | ||||
| sCD8, sIL-2R, neopterin | ↑ Patients refractory to treatment | Caldas et al., | |||
| MCP-1 | ↑ Asymptomatic VL ↑ Cured patients | Kaye and Scott, | |||
| IL-6 | ↑ Fatal Disease (higher risk of death) | Costa et al., | |||
| IL-1β, IL-8, and TNF-α, IFN-γ, IL-27, IL-10 | Severity of disease | Dos Santos et al., | |||
| sCD14 | ↑ Severe disease | Dos Santos et al., | |||
| IL-1β, IL-6 IL-8 TGF-β1 | PGF2α, LTB4, RvD1 | ↓ Active ZVL Post-treatment | Araujo-Santos et al., | ||
| – | FGF, VEGF | ↑ Active VL | Duthie et al., |
Biomarkers in canine visceral leishmaniasis.
| IFN- γ, IL-2 and TNF-α | ↑ Resistance to infection | Reis et al., | |||
| ↑ Beginning of infection | Rodriguez-Cortes et al., | ||||
| IL-4, IL-5, IL-13 and IL- 10 TGF-β | ↑ Susceptibility to infection ↑ Chronic phase | Reis et al., | |||
| IRP2 (iron regulatory protein 2) | ↑ Susceptible dogs | do Nascimento et al., | |||
| CD163 (M2 macrophages) | ↑ In macrophages from spleen and lymph nodes with ↑ parasite load | Moreira et al., | |||
| PD-1-PDL-1 | ↑ Symptomatic dog-exhaustion of CD4 AND CD8 T cells | Esch et al., | |||
| IFN-γ, GM-CSF, IL-6, and IL-18 | ↑ Dogs infected by 6 years without clinical signs | Abbehusen et al., | |||
| TNF, IL-2 | CXCL1 | ↓ Dogs infected by 6 years without clinical signs | |||
| LTB-4 and PGE-2 | ↓ Dogs with severe disease | Solca et al., | |||
| CCL2, CCXL1 | ↑ |